drugset / Trial / NCT03048383

Comparison of Three Botulinum Neuromodulators for Management of Facial Synkinesis

NCT03048383

Phase 4 Completed 71 enrolled University of Utah
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to compare the effectiveness of three commercially available botulinum toxin neuromodulators in the treatment of facial synkinesis using patient reported outcome measures.

Timeline

Start
2012-07
Primary completion
2015-03
Completion
2015-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic Other

Indications